- Rapid Dose Therapeutics (CSE:DOSE) submitted a product application to Health Canada for its QuickStrip nicotine products in 1 mg to 4 mg formats, a big step toward commercialization
- QuickStrip is a fast-dissolving oral thin film designed to deliver nicotine, currently undergoing clinical trials comparing its efficacy to traditional cigarettes
- RDT’s innovation aims to align with Canada’s tobacco reduction goals and global harm reduction efforts, with plans for national launch and international expansion upon approval
- Rapid Dose Therapeutics stock (CSE:DOSE) last traded at $0.17
Rapid Dose Therapeutics (CSE:DOSE) officially submitted a product application to Health Canada for its QuickStrip nicotine products in 1 mg, 2 mg, 3 mg, and 4 mg formats. This regulatory milestone marks a pivotal step toward the commercialization of RDT’s proprietary oral nicotine delivery system, developed as a safer alternative to smoking.
This content has been prepared as part of a partnership with Rapid Dose Therapeutics Corp. and is intended for informational purposes only.
QuickStrip is a fast-dissolving oral thin film designed to deliver active ingredients directly through the oral mucosa. The NicStrip product line utilizes this platform to offer nicotine in a controlled, smoke-free format, aimed at helping adult smokers reduce or quit tobacco use. The product is currently undergoing a pharmacokinetic clinical trial comparing QuickStrip Nicotine to traditional combustible cigarettes to evaluate absorption and efficacy. The study, conducted under Good Clinical Practice guidelines, is expected to provide critical data on nicotine bioavailability and support product claims for regulatory approval.
“Our QuickStrip delivery system is designed to mimic the nicotine absorption curve of a cigarette without the harmful by products of combustion,” Jason Lewis, RDT’S senior vice president explained in news release. “It provides rapid onset, consistent dosing, and eliminates second-hand smoke-critical attributes for any successful smoking cessation or harm reduction strategy.”
Over the past 30 months, RDT has collaborated with a leading global cigarette manufacturer to refine the QuickStrip nicotine product in preparation for launch. This strategic partnership has enabled extensive research and development focused on product optimization. In parallel, RDT and its production partner Aavishkar have filed two international patent applications under the Patent Cooperation Treaty, covering innovations in nicotine delivery, film formulation, and controlled-release technology.
The inclusion of multiple dose strengths allows users to personalize their nicotine intake and taper use over time, supporting individualized cessation plans. Upon regulatory approval, RDT plans to launch the product across Canada and expand distribution through commercial partnerships, including potential licensing in international markets.
This initiative aligns with the Government of Canada’s Tobacco Strategy, which aims to reduce tobacco use to less than 5 per cent by 2035, and supports the World Health Organization’s goal of reducing adult smoking prevalence by 30 per cent by 2030 under the WHO Framework Convention on Tobacco Control.
Rapid Dose Therapeutics previously submitted a nicotine product application to Health Canada in 2019, but the process was delayed due to the COVID-19 pandemic.
The Canadian nicotine pouches market was valued at US$112.2 million in 2024, with projected annual growth of 4.7 per cent through 2030, driven by increased demand for discreet, smoke-free alternatives and a growing public health focus on harm reduction.
About Rapid Dose Therapeutics
Rapid Dose Therapeutics Corp. is a Canadian life sciences company committed to developing and commercializing innovative drug delivery technologies. Its flagship QuickStrip platform offers rapid, convenient, and effective delivery of active ingredients, supporting a wide range of therapeutic applications.
Rapid Dose Therapeutics stock (CSE:DOSE) last traded at $0.17 and has lost 20.45 per cent since the year began.
Join the discussion: Find out what the Bullboards are saying about Rapid Dose Therapeutics and check out Stockhouse’s stock forums and message boards.
Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein. For full disclaimer information, please click here.
